|
Volumn 4, Issue 4, 2004, Pages 368-371
|
New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADALIMUMAB;
ALEFACEPT;
ANTISENSE OLIGONUCLEOTIDE;
CELL ADHESION MOLECULE;
CHEMOKINE;
CHEMOKINE RECEPTOR CCR1 ANTAGONIST;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
ETANERCEPT;
IMMUNOMODULATING AGENT;
INFLIXIMAB;
INTERLEUKIN 1 ANTIBODY;
INTERLEUKIN 1BETA ANTIBODY;
INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR;
INTERLEUKIN 6 ANTIBODY;
KELIXIMAB;
LENERCEPT;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY LM 609;
RECEPTOR BLOCKING AGENT;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RITUXIMAB;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNCLASSIFIED DRUG;
ARTICLE;
CHRONIC INFLAMMATION;
CLINICAL TRIAL;
HUMAN;
IMMUNOMODULATION;
INFLAMMATORY DISEASE;
LIVER TOXICITY;
NONHUMAN;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SIGNAL TRANSDUCTION;
|
EID: 3342885539
PISSN: 14714892
EISSN: None
Source Type: Journal
DOI: 10.1016/j.coph.2004.05.003 Document Type: Editorial |
Times cited : (5)
|
References (6)
|